Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. BDRX
BDRX logo

BDRX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.979
Open
0.950
VWAP
0.95
Vol
58.73K
Mkt Cap
796.76K
Low
0.907
Amount
55.54K
EV/EBITDA(TTM)
--
Total Shares
838.79K
EV
-4.27M
EV/OCF(TTM)
--
P/S(TTM)
--
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Show More

Events Timeline

(ET)
2026-02-04
08:40:00
Biodexa Closes Exclusive License with Otsuka Pharmaceutical for OPB-171775
select
2026-01-05 (ET)
2026-01-05
08:40:00
Biodexa Appoints Fiona Sharp as CFO and Company Secretary
select
2025-12-18 (ET)
2025-12-18
08:40:00
Biodexa Pharmaceuticals Prices Public Offering at $3.28
select
2025-12-08 (ET)
2025-12-08
09:40:00
Biodexa Pharmaceuticals PLC-ADR Trading Halted Due to Volatility
select
2025-12-01 (ET)
2025-12-01
08:41:00
Biodexa Enrolls First Patients in Phase 3 Serenta Trial of eRapa for Colorectal Cancer
select
2025-11-24 (ET)
2025-11-24
08:42:25
Biodexa Pharmaceuticals Launches First European Site for Phase 3 Serenta Study
select
2025-11-03 (ET)
2025-11-03
08:34:39
Biodexa Receives EMA Approval for Phase 3 Trial CTA in FAP
select
2025-09-12 (ET)
2025-09-12
08:38:15
Biodexa Indicates Financing Needs Create 'Significant Uncertainty'
select

News

Newsfilter
7.5
03-09Newsfilter
Biodexa Supports Life's a Polyp Foundation for FAP Patients
  • First FAP Advocacy Group: Biodexa Pharmaceuticals PLC officially supports the launch of the Life's a Polyp Foundation, the first U.S.-based advocacy group dedicated to patients with Familial Adenomatous Polyposis (FAP), aiming to provide essential resources and support while raising awareness of this rare genetic condition.
  • Financial Support and Collaboration: Biodexa has provided initial financial grants to the foundation, demonstrating its commitment to addressing unmet needs of FAP patients and amplifying patient voices in rare disease research and care through collaboration with the foundation.
  • Innovative Treatment Program: Biodexa's lead program, eRapa, is currently in the registrational Phase 3 Serenta trial as the first potential non-surgical treatment for FAP, with over 20% of patients enrolled and Fast Track designation from the FDA, indicating its potential to enhance patient survival rates.
  • Patient-Centric Mission: Steve Ellul, Biodexa's CBO, emphasized that supporting the Life's a Polyp Foundation aligns with their goal to improve the lives of FAP patients through advocacy, innovation, and collaboration, reflecting the company's strong commitment to patient-centric initiatives.
Newsfilter
8.5
02-04Newsfilter
Biodexa Secures Exclusive License for Otsuka's OPB-171775, a Novel GIST Treatment
  • Exclusive Licensing Agreement: Biodexa has entered into an exclusive licensing agreement with Otsuka Pharmaceutical to develop and commercialize OPB-171775 globally, except in Japan, which is expected to significantly enhance the company's market position in rare diseases.
  • Innovative Mechanism: MTX240 utilizes molecular glue technology to effectively overcome TKI resistance by inducing interactions between PDE3a and SLFN12 proteins, offering a novel therapeutic approach that may benefit a large number of GIST patients.
  • Market Potential: With approximately 3,000-4,000 GIST patients annually in the U.S., MTX240's unique mechanism is poised to address the treatment gap for TKI-resistant patients, and the global GIST market is projected to grow at an annual rate of 6-10% to reach about $1.3 billion by 2032.
  • Patent Protection: MTX240 is protected by composition of matter patents in the U.S., Europe, and Japan, extending through 2037, ensuring its competitive advantage in the market while providing legal safeguards for future development and commercialization.
NASDAQ.COM
5.0
01-05NASDAQ.COM
Biodexa Pharmaceuticals Appoints Fiona Sharp as CFO, Shares Rise 3.45%
  • Executive Transition: Biodexa Pharmaceuticals has promoted Fiona Sharp to Chief Financial Officer and Company Secretary, effective immediately, aiming to strengthen financial management and enhance operational efficiency within the company.
  • Succession Plan: Sharp succeeds Stephen Stamp, who will continue as Chief Executive Officer, ensuring stability and continuity in the company's leadership during this transition.
  • Financial Expertise: Having served as Group Financial Controller since December 2019, Sharp brings extensive financial management experience, previously holding the position of Assistant Director of Finance at Hywel Dda University Health Board, which is expected to enhance the company's financial strategy.
  • Market Reaction: BDRX shares are currently trading at $2.54, reflecting a 3.45% increase from the previous trading day, indicating positive market sentiment regarding the new CFO's appointment and confidence in the company's future growth prospects.
Benzinga
9.5
2025-12-16Benzinga
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
  • B. Riley Financial Performance: B. Riley Financial Inc reported a significant turnaround with earnings of $4.50 per share for Q2, compared to a loss of $14.35 per share a year ago, and sales increased to $225.302 million from $94.885 million, leading to a 25% rise in share price during pre-market trading.

  • Pre-Market Stock Movements: Several stocks experienced notable pre-market trading movements, with Biodexa Pharmaceuticals gaining 51.4% and Venus Concept surging 31.1%, while Radiopharm Theranostics saw a sharp decline of 39.8%.

  • Other Notable Gainers: Other stocks that rose in pre-market trading included Uniqure NV (+14.1%), Adagio Medical Holdings (+11.7%), and Sunrise New Energy (+10.5%), reflecting a mix of recovery and growth in various sectors.

  • Significant Losers: Stocks that faced declines included iRobot Corp, which fell 23.2% after filing for Chapter 11 bankruptcy, and Saverone 2014 Ltd, which tumbled 37.8% following a previous gain, indicating volatility in the market.

Benzinga
9.5
2025-12-09Benzinga
Mama's Creations Stock Rises Over 13%; Check Out 20 Stocks Making Moves in Premarket Trading
  • Mama's Creations Inc Performance: Shares of Mama's Creations Inc rose 13.3% in pre-market trading after reporting third-quarter earnings of 1 cent per share, surpassing analyst expectations of a loss of 2 cents, along with sales of $47.269 million exceeding the $43.203 million estimate.

  • Other Notable Gainers: Several stocks saw significant gains in pre-market trading, including Alphatime Acquisition Corp (up 388.8%), Exicure Inc (up 103.4%), and Netcapital Inc (up 88.5%), driven by positive news such as merger approvals and favorable trial results.

  • Stocks Experiencing Losses: Conversely, Top Wealth Group Holding Ltd experienced a sharp decline of 49.3% after a previous surge, along with other companies like Orangekloud Technology Inc and Biodexa Pharmaceuticals PLC, which fell 36.1% and 17.2%, respectively.

  • Market Movements: Ares Management Corp will replace Kellanova in the S&P 500, while Sezzle Inc will replace Vital Energy in the S&P SmallCap 600, indicating ongoing shifts in market indices.

Newsfilter
2.0
2025-11-24Newsfilter
Biodexa Activates First European Site for Phase 3 Serenta Trial in FAP
  • Trial Activation: Biodexa Pharmaceuticals has activated its first European site for the Phase 3 Serenta clinical trial at the University of Bonn, Germany, focusing on familial adenomatous polyposis (FAP). This milestone offers new hope for FAP patients who currently lack approved non-surgical treatment options.
  • Funding Support: The trial's launch is supported by a $20 million grant from the Cancer Prevention and Research Institute of Texas, along with collaborations with Emtora Biosciences and Precision for Medicine. This backing strengthens Biodexa's competitive position in the cancer treatment landscape in Europe.
  • Trial Design: The Serenta trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy of eRapa in preventing disease progression in FAP patients. Given that untreated FAP leads to colorectal cancer in nearly all patients by age 50, the trial's success could significantly enhance patient quality of life.
  • Future Plans: Nine additional European sites are expected to activate over the next 2-3 months across the Netherlands, Spain, Denmark, and Italy. This expansion will further bolster Biodexa's presence in the European market and provide treatment opportunities for more FAP patients.

Valuation Metrics

The current forward P/E ratio for Biodexa Pharmaceuticals PLC (BDRX.O) is -7.31, compared to its 5-year average forward P/E of -54.48. For a more detailed relative valuation and DCF analysis to assess Biodexa Pharmaceuticals PLC's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-54.48
Current PE
-7.31
Overvalued PE
128.27
Undervalued PE
-237.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.96
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.26
Undervalued EV/EBITDA
-3.18

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
46.12
Current PS
0.00
Overvalued PS
136.53
Undervalued PS
-44.30

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

list of IPO from 2023
Intellectia · 1210 candidates
Region: USFloating Shares: <= 20,000,000
Ticker
Name
Market Cap$
top bottom
LGHL logo
LGHL
Lion Group Holding Ltd
623.70K
RAYA logo
RAYA
Erayak Power Solution Group Inc
684.91K
BDRX logo
BDRX
Biodexa Pharmaceuticals PLC
792.57K
ADTX logo
ADTX
Aditxt Inc
829.40K
BNRG logo
BNRG
Brenmiller Energy Ltd
859.02K
TRNR logo
TRNR
Interactive Strength Inc
865.12K
Low float stock screener
Intellectia · 1484 candidates
List Exchange: XNYS, XNAS, XASEFloating Shares: <= 20,000,000
Ticker
Name
Market Cap$
top bottom
LGHL logo
LGHL
Lion Group Holding Ltd
638.91K
LRHC logo
LRHC
La Rosa Holdings
711.55K
RAYA logo
RAYA
Erayak Power Solution Group Inc
831.04K
NIVF logo
NIVF
NewGenIvf Group Ltd
864.77K
QH logo
QH
Quhuo Ltd
948.08K
BDRX logo
BDRX
Biodexa Pharmaceuticals PLC
1.01M

Whales Holding BDRX

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Biodexa Pharmaceuticals PLC (BDRX) stock price today?

The current price of BDRX is 0.9499 USD — it has increased 0

What is Biodexa Pharmaceuticals PLC (BDRX)'s business?

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.

What is the price predicton of BDRX Stock?

Wall Street analysts forecast BDRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDRX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Biodexa Pharmaceuticals PLC (BDRX)'s revenue for the last quarter?

Biodexa Pharmaceuticals PLC revenue for the last quarter amounts to NaN USD, decreased

What is Biodexa Pharmaceuticals PLC (BDRX)'s earnings per share (EPS) for the last quarter?

Biodexa Pharmaceuticals PLC. EPS for the last quarter amounts to USD, decreased

How many employees does Biodexa Pharmaceuticals PLC (BDRX). have?

Biodexa Pharmaceuticals PLC (BDRX) has 16 emplpoyees as of March 11 2026.

What is Biodexa Pharmaceuticals PLC (BDRX) market cap?

Today BDRX has the market capitalization of 796.76K USD.